Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?
The biotech player could eventually rival big pharma companies.
Overview
Today, a very valuable market -- one heading toward $100 billion by the end of the decade -- is dominated by two pharma giants, Eli Lilly and Novo Nordisk. And this is the weight loss drug market. Lilly and Novo each sell GLP-1 drugs, products that have seen soaring demand and have delivered blockbuster revenue.
But a new potential player is waiting in the wings and has been taking important steps forward. Viking Therapeutics (NASDAQ:VKTX) is testing its candidate, VK2735, in late-stage trials in injectable and oral formulations, and so far, data have been strong. Just this week, the company released an exciting update from a maintenance dosing study of its injectable formulation. That prompted the stock to soar 35% in one trading session.
Details
Now, the question is: Is it too late to buy this potential GLP-1 winner? Let's find out.
Source
Originally published at www.fool.com.
Related Articles
- Why the alternative to the ‘clear and present’ danger from bond yields is this AI-fueled market that’s quietly outperformed
- Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
- NIH funding cuts delayed a promising childhood brain cancer trial. Patients lost time they didn't have.